Analysis of the Prevalence of Obstructive Sleep Apnea-h ypopnea Syndrome among Patients with Heart Failure and the Therapeutic Efficacy of Continuous Positive Airway Pressure Ventilation
YAO Liqin
ZHENG Shuguang
JIA Guoping
GUO Xiangxiang
Abstract：Objective: To analyze the prevalence of obstructive sleep apnea-hypopnea syndrome (OSAHS) among hospitalized patients with heart failure and the therapeutic effect of continuous positive airway pressure (CPAP). Methods: This study was a single-center, prospective cohort study. A total of 100 patients with heart failure (NYHA class II or III) admitted to Shanxi Cardiovascular Hospital from January 2019 to December 2021 were consecutively enrolled. All participants underwent polysomnography (PSG). Patients with OSAHS were included in the observation group (48 cases), while those without OSAHS were included in the control group (52 cases). General data (including age, gender, height, weight, history of hypertension, lipid levels, uric acid) and heart function indicators [N-terminal pro-B-type natriuretic peptide (NT-proBNP), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)] were collected. After discharge, follow-up was conducted, and treatment was guided. The observation group received drug therapy combined with CPAP, while the control group received only drug therapy. The levels of NT-proBNP, LVEDD, LVEF, and the readmission rate within 90 days after discharge were compared between the two groups. Results: After 90 days of treatment, the apnea-hypopnea index (AHI) in the observation group decreased significantly compared to before treatment (P < 0.05). After treatment, both groups showed a significant decrease in NT-proBNP and LVEDD, and an increase in LVEF (P < 0.05). Moreover, the observation group had a greater reduction in NT-proBNP and LVEDD and a greater increase in LVEF compared to the control group (P < 0.05). The readmission rate within 90 days after discharge in the observation group was lower than that in the control group (P < 0.05). Conclusion: OSAHS is a common comorbidity in hospitalized patients with heart failure. Treatment with drugs combined with CPAP can reduce AHI, NT-proBNP, and LVEDD, improve LVEF, and to some extent reduce the risk of readmission within 90 days after discharge.
Keywords：heart failureobstructive sleep apnea hypopnea syndromecontinuous positive airway pressure
Publication Date：2025-08-25
Online Publishing Date：2025-09-10(First online date of this platform, not the publication date of the document)
Pages：4( 2516-2519 )